期刊文献+

多色免疫荧光技术在胃癌免疫治疗中的临床应用

Clinical Application of Multiplex Immunofluorescence Technique in Immunotherapy of Gastric Cancer
下载PDF
导出
摘要 胃癌是我国常见的恶性肿瘤,其治疗现已进入免疫治疗时代。多色免疫荧光技术是近年出现的一项新兴检测技术,包括多色免疫荧光染色、多光谱成像和组织软件定量分析三个环节,能对肿瘤免疫微环境中特异性免疫细胞群进行共定位分析。国内外已有大量研究利用多色免疫荧光技术实现胃癌免疫微环境中不同细胞亚群及其分子表达的检测,并在胃癌治疗和预后评估方面显示出重要的临床价值。尽管存在一定局限性,但与传统方法相比,该技术具有高重复性、高效率、高成本效益等优点。本文就多色免疫荧光技术在胃癌免疫治疗中的临床应用作一综述。 Gastric cancer is a common malignant tumor in China.The treatment of gastric cancer has entered the era of immunotherapy.Multiplex immunofluorescence technology is a new detection technology in recent years,including multiplex immunofluorescence staining,multispectral imaging and tissue quantitative analysis,which can co-locate specific immune cell populations in tumor immune microenvironment.A large number of studies used multiplex immunofluorescence technology to detect different cell subsets and their molecular expression in the immune microenvironment of gastric cancer,which had shown important clinical value in the treatment and prognosis evaluation of gastric cancer.This technique has certain limitation,but it has much advantages,such as high repeatability,high efficiency and high cost-effectiveness compared with traditional methods.This article reviewed the clinical application of multiplex immunofluorescence technique in immunotherapy of gastric cancer.
作者 吴杨 陈卫昌 WU Yang;CHEN Weichang(Department of Gastroenterology,the First Affiliated Hospital of Soochow University,Suzhou,Jiangsu Province215006)
出处 《胃肠病学》 北大核心 2021年第11期697-701,共5页 Chinese Journal of Gastroenterology
基金 江苏省社会发展临床前沿技术重点项目(BE2020656) 姑苏卫生人才培养项目(GSWS201903)。
关键词 胃肿瘤 多色免疫荧光 免疫疗法 Stomach Neoplasms Multiplex Immunofluorescence Immunotherapy
  • 相关文献

参考文献1

二级参考文献12

  • 1Viguier M, Lemax~tre F, Verola O, et al. Foxp3 expressing CIM + CD25 (high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells [ J ]. J Immunol, 2004, 173 (2) : 1444-1453.
  • 2Srivastava MK, Sinha P, Clements VK, et al. Myeloid- derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine[ J]. Cancer Res, 2010, 70 (1) : 68-77.
  • 3Edge S, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual[ M]. 7th ed. New York: Springer, 2010: 117-126.
  • 4Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance [ J ]. Nat Rev Cancer, 2005, 5 (4) : 263-274.
  • 5Bhardwaj N. Harnessing the immune system to treat cancer [J]. J Clin Invest, 2007, 117 (5) : 1130-1136.
  • 6Ohkura N, Hamaguchi M, Sakaguchi S. FOXP3 + regulatory T cells: control of FOXP3 expression by pharmacological agents [ J]. Trends Pharmacol Sci, 2011, 32 (3) : 158-166.
  • 7Cao X, Cai SF, Fehniger TA, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance [ J ]. Immunity, 2007, 27 (4) : 635-646.
  • 8Boissonnas A, Seholer-Dahirel A, Simon-Blaneal V, et al. Foxp3 + T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes [ J ]. Immunity, 2010, 32 (2): 266-278.
  • 9Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3 + regulatory T cell function [ J ]. Science, 2008, 322 (5899): 271-275.
  • 10Diaz-Montero CM, Salem ML, Nishimura MI, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy [ J ]. Cancer Immunol Immunother, 2009, 58 ( I ) : 49-59.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部